ABT logo

ABT
Abbott Laboratories

17,958
Mkt Cap
$153.94B
Volume
8.52M
52W High
$139.06
52W Low
$81.97
PE Ratio
24.45
ABT Fundamentals
Price
$87.77
Prev Close
$88.38
Open
$88.60
50D MA
$96.48
Beta
0.25
Avg. Volume
12.46M
EPS (Annual)
$3.72
P/B
2.94
Rev/Employee
$385,460.87
$224,844.92
Loading...
Loading...
News
all
press releases
ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?
News Placeholder
More News
News Placeholder
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
News Placeholder
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
News Placeholder
Boston Scientific Bets on Growth Through Strategic M&A Deals
BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.
News Placeholder
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
News Placeholder
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
News Placeholder
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.
News Placeholder
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment...
News Placeholder
Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.
News Placeholder
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?
ABT's Q1 beat was overshadowed by Exact Sciences dilution, legal risks and weak Diagnostics trends as shares hit a 52-week low.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available